EP 1335745 A1 20030820 - USE OF A COMPOUND ANTAGONIST OF THE ESM-1 PROTEIN FOR PRODUCING A MEDICINE FOR TREATING CANCER
Title (en)
USE OF A COMPOUND ANTAGONIST OF THE ESM-1 PROTEIN FOR PRODUCING A MEDICINE FOR TREATING CANCER
Title (de)
VERWENDUNG VON EINEM ESM-1 PROTEIN-ANTAGONIST ZUR HERSTELLUNG EINES MEDIKAMENTS FÜR DIE BEHANDLUNG VON KREBS
Title (fr)
UTILISATION D'UN COMPOSE ANTAGONISTE DE LA PROTEINE ESM-1 POUR LA FABRICATION D'UN MEDICAMENT POUR LE TRAITEMENT D'UN CANCER
Publication
Application
Priority
- FR 0103475 W 20011108
- FR 0014422 A 20001109
Abstract (en)
[origin: FR2816214A1] Use of an antagonist (I) of endothelial cell-specific molecule-1 (II) for treatment of cancer, is new. Independent claims are also included for the following: (1) antagonist of (II) that is the monoclonal antibody produced by hybridoma MEC15 (CNCM I-2572); and (2) methods for selecting (I).
IPC 1-7
A61K 39/395; A61K 38/17; A61K 31/7088; G01N 33/53; A61P 35/00
IPC 8 full level
A61K 39/395 (2006.01); G01N 33/50 (2006.01); A61K 31/7088 (2006.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 45/00 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); G01N 33/15 (2006.01); G01N 33/53 (2006.01)
CPC (source: EP US)
A61P 35/00 (2017.12 - EP); C07K 14/47 (2013.01 - EP US); C07K 16/18 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US); A61K 2039/505 (2013.01 - EP US)
Citation (search report)
See references of WO 0238178A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
FR 2816214 A1 20020510; FR 2816214 B1 20051021; AU 1834202 A 20020521; CA 2429404 A1 20020506; EP 1335745 A1 20030820; JP 2004518638 A 20040624; JP 4121852 B2 20080723; US 2004234526 A1 20041125; US 7306797 B2 20071211; WO 0238178 A1 20020516
DOCDB simple family (application)
FR 0014422 A 20001109; AU 1834202 A 20011108; CA 2429404 A 20011108; EP 01993475 A 20011108; FR 0103475 W 20011108; JP 2002540760 A 20011108; US 41620304 A 20040426